# Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

> **NCT07527858** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 170 (estimated)

## Conditions studied

- Advanced Microsatellite Stable Colorectal Cancer

## Interventions

- **DRUG:** Denikitug
- **DRUG:** Nivolumab
- **DRUG:** Bevacizumab
- **DRUG:** Trifluridine-Tipiracil

## Key facts

- **NCT ID:** NCT07527858
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527858, "Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07527858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*